GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adynxx Inc (OTCPK:ADYX) » Definitions » Inventory-to-Revenue

Adynxx (Adynxx) Inventory-to-Revenue : 0.00 (As of Sep. 2019)


View and export this data going back to 1998. Start your Free Trial

What is Adynxx Inventory-to-Revenue?

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Adynxx's Average Total Inventories for the quarter that ended in Sep. 2019 was $0.00 Mil. Adynxx's Revenue for the three months ended in Sep. 2019 was $0.00 Mil.

Adynxx's Inventory-to-Revenue for the quarter that ended in Sep. 2019 stayed the same from Jun. 2019 (0.00) to Jun. 2019 (0.00)

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.


Adynxx Inventory-to-Revenue Historical Data

The historical data trend for Adynxx's Inventory-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adynxx Inventory-to-Revenue Chart

Adynxx Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Inventory-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.20 0.15 0.14 0.56 0.04

Adynxx Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
Inventory-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.46 0.31 0.82 - -

Competitive Comparison of Adynxx's Inventory-to-Revenue

For the Biotechnology subindustry, Adynxx's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Adynxx's Inventory-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adynxx's Inventory-to-Revenue distribution charts can be found below:

* The bar in red indicates where Adynxx's Inventory-to-Revenue falls into.



Adynxx Inventory-to-Revenue Calculation

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Adynxx's Inventory-to-Revenue for the fiscal year that ended in Dec. 2018 is calculated as

Inventory-to-Revenue (A: Dec. 2018 )
=Average Total Inventories / Revenue
=( (Total Inventories (A: Dec. 2017 ) + Total Inventories (A: Dec. 2018 )) / count ) / Revenue (A: Dec. 2018 )
=( (0.093 + 0.101) / 2 ) / 2.216
=0.097 / 2.216
=0.04

Adynxx's Inventory-to-Revenue for the quarter that ended in Sep. 2019 is calculated as

Inventory-to-Revenue (Q: Sep. 2019 )
=Average Total Inventories / Revenue
=( (Total Inventories (Q: Jun. 2019 ) + Total Inventories (Q: Sep. 2019 )) / count ) / Revenue (Q: Sep. 2019 )
=( (0 + 0) / 1 ) / 0
=0 / 0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Adynxx  (OTCPK:ADYX) Inventory-to-Revenue Explanation

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.

Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.

More Related Terms:

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Adynxx's Days Inventory for the three months ended in Sep. 2019 is calculated as:

Days Inventory=Average Total Inventories (Q: Sep. 2019 )/Cost of Goods Sold (Q: Sep. 2019 )*Days in Period
=0/0*365 / 4
=

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Adynxx's Inventory Turnover for the quarter that ended in Sep. 2019 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Sep. 2019 ) / Average Total Inventories (Q: Sep. 2019 )
=0 / 0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Adynxx Inventory-to-Revenue Related Terms

Thank you for viewing the detailed overview of Adynxx's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Adynxx (Adynxx) Business Description

Traded in Other Exchanges
N/A
Address
100 Pine Street, Suite 500, San Francisco, CA, USA, 94111
Adynxx Inc is a United States-based clinical-stage biopharmaceutical company. It is focused on the development of a new class of therapeutics called transcription factor decoys and bringing to the market novel, disease-modifying products to address unmet needs in the treatment of pain and inflammation. Its pipeline includes brivoligide, a Phase 2 drug candidate intended to address postoperative pain, and AYX2, a pre-clinical candidate intended to treat chronic syndromes of pain, including both inflammatory and neuropathic pain.
Executives
Gregory J. Flesher director 19900 MACARTHUR BLVD., SUITE 550, IRVINE CA 92612
Brian H Dovey 10 percent owner ONE PALMER SQUARE, PRINCETON NJ 08542
Donald C. Manning officer: CHIEF MEDICAL OFFICER C/O PACIRA BIOSCIENCES, INC., 5 SYLVAN WAY, SUITE 300, PARSIPPANY NJ 07054
Pierre Legault director P.O. BOX 1028, C/O STONE MANAGEMENT LLC, BERWYNE PA 19312
Domain Partners Viii, L.p. 10 percent owner C/O DOMAIN ASSOCIATES, L.L.C., ONE PALMER SQUARE, SUITE 515, PRINCETON NJ 08542
Dp Viii Associates, L.p. 10 percent owner C/O DOMAIN ASSOCIATES, L.L.C., ONE PALMER SQUARE, SUITE 515, PRINCETON NJ 08542
Eckard Weber director C/O DOMAIN ASSOCIATES, ONE PALO SQ, PRINCETON NJ 08542
Brian K Halak 10 percent owner C/O DOMAIN ASSOCIATES, ONE PALMER SQUARE, PRINCETON NJ 08542
Nicole Vitullo 10 percent owner 3030 SCIENCE PARK ROAD, SAN DIEGO CA 92121
James C Blair 10 percent owner 5880 PACIFIC CENTER BLVD, SAN DIEGO CA 92121-4204
Jesse I Treu 10 percent owner
Dennis Podlesak director C/O PENINSULA PHARMACEUTICALS, INC., 1751 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Tpg Group Holdings (sbs) Advisors, Inc. 10 percent owner C/O TPG GLOBAL, LLC, 301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102
James G Coulter 10 percent owner 301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102
David Bonderman 10 percent owner 301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102

Adynxx (Adynxx) Headlines

From GuruFocus

Adynxx Reports Third Quarter 2019 Financial Results

By Marketwired Marketwired 11-14-2019

CFO of Alliqua BioMedical Inc Buys 2,500 Shares

By Jennifer Chiou Jennifer Chiou 08-12-2015

Celleration Acquisition Just the Start of Alliqua's M&A Strategy

By Last Financier Last Financier 02-04-2015